Tuberculosis and Respiratory Diseases

The Korean Academy of Tuberculosis and Respiratory Diseases (대한결핵및호흡기학회)
권호 표지
DOI QR코드

DOI QR Code

Treatment Outcomes of Patients with Multidrug-Resistant Tuberculosis: Concern to Bedaquiline: Authors' Reply

  • Kang, Yewon (Department of Internal Medicine, Dongkang Medical Center) ;
  • Mok, Jeongha (Department of Internal Medicine, Pusan National University Hospital)
  • Received : 2021.09.05
  • Accepted : 2021.09.12
  • Published : 2022.01.31
Download PDF
⟨ Previous Next ⟩

Abstract

Keywords

References

  1. Putra ON, Hidayatllah AY. Treatment outcomes of patients with multidrug-resistant tuberculosis: concern to bedaquiline. Tuberc Respir Dis 2021;84:338-9. https://doi.org/10.4046/trd.2021.0115
  2. Kang Y, Jo EJ, Eom JS, Kim MH, Lee K, Kim KU, et al. Treatment outcomes of patients with multidrug-resistant tuberculosis: comparison of pre- and post-public-private mix periods. Tuberc Respir Dis 2021;84:74-83. https://doi.org/10.4046/trd.2020.0093
  3. Diacon AH, Pym A, Grobusch MP, de los Rios JM, Gotuzzo E, Vasilyeva I, et al. Multidrug-resistant tuberculosis and culture conversion with bedaquiline. N Engl J Med 2014;371:723-32. https://doi.org/10.1056/NEJMoa1313865
  4. Schnippel K, Ndjeka N, Maartens G, Meintjes G, Master I, Ismail N, et al. Effect of bedaquiline on mortality in South African patients with drug-resistant tuberculosis: a retrospective cohort study. Lancet Respir Med 2018;6:699-706. https://doi.org/10.1016/S2213-2600(18)30235-2
  5. Collaborative Group for the Meta-Analysis of Individual Patient Data in MDR-TB treatment-2017; Ahmad N, Ahuja SD, Akkerman OW, Alffenaar JC, Anderson LF, et al. Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis. Lancet 2018;392:821-34. https://doi.org/10.1016/S0140-6736(18)31644-1
  6. World Health Organization. WHO consolidated guidelines on tuberculosis. Module 4: treatment: drug-resistant tuberculosis treatment. Geneva: World Health Organization; 2020.
  7. Kempker RR, Mikiashvili L, Zhao Y, Benkeser D, Barbakadze K, Bablishvili N, et al. Clinical outcomes among patients with drug-resistant tuberculosis receiving bedaquiline- or delamanid-containing regimens. Clin Infect Dis 2020;71:2336-44.
  8. Brust JC, Gandhi NR, Wasserman S, Maartens G, Omar SV, Ismail NA, et al. Effectiveness and cardiac safety of bedaquiline-based therapy for drug-resistant tuberculosis: a prospective cohort study. Clin Infect Dis 2021 Apr 21 [Epub]. https://doi.org/10.1093/cid/ciab335.
  9. Dooley KE, Rosenkranz SL, Conradie F, Moran L, Hafner R, von Groote-Bidlingmaier F, et al. QT effects of bedaquiline, delamanid, or both in patients with rifampicin-resistant tuberculosis: a phase 2, open-label, randomised, controlled trial. Lancet Infect Dis 2021;21:975-83. https://doi.org/10.1016/S1473-3099(20)30770-2
  10. Lan Z, Ahmad N, Baghaei P, Barkane L, Benedetti A, Brode SK, et al. Drug-associated adverse events in the treatment of multidrug-resistant tuberculosis: an individual patient data meta-analysis. Lancet Respir Med 2020;8:383-94. https://doi.org/10.1016/s2213-2600(20)30047-3
  11. Lee A, Xie YL, Barry CE, Chen RY. Current and future treatments for tuberculosis. BMJ 2020;368:m216.